<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34379200</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Role of the nigrosome 1 absence as a biomarker in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1631</StartPage><EndPage>1640</EndPage><MedlinePgn>1631-1640</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10729-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The absence of nigrosome 1 on brain MRI and the hyperechogenicity of substantia nigra (SNh) by transcranial sonography are two useful biomarkers in the diagnosis of parkinsonisms. We aimed to evaluate the absence of nigrosome 1 in amyotrophic lateral sclerosis (ALS) and to address its meaning.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">136 ALS patients were recruited, including 16 progressive muscular atrophy (PMA) and 22 primary lateral sclerosis (PLS) patients. The SNh area was measured planimetrically by standard protocols. The nigrosome 1 status was qualitatively assessed by two blind evaluators in susceptibility weight images of 3T MRI. Demographic and clinical data were collected and the C9ORF72 expansion was tested in all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nigrosome 1 was absent in 30% of ALS patients (36% of PLS, 29% of classical ALS and 19% of PMA patients). There was no relationship between radiological and clinical laterality, nor between nigrosome 1 and SNh area. Male sex (OR&#x2009;=&#x2009;3.63 [1.51, 9.38], p&#x2009;=&#x2009;0.005) and a higher upper motor neuron (UMN) score (OR&#x2009;=&#x2009;1.10 [1.02, 1.2], p&#x2009;=&#x2009;0.022) were independently associated to nigrosome 1 absence, which also was an independent marker of poor survival (HR&#x2009;=&#x2009;1.79 [1.3, 2.8], p&#x2009;=&#x2009;0.013).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In ALS patients, the absence of nigrosome 1 is associated with male sex, UMN impairment and shorter survival. This suggests that constitutional factors and the degree of pyramidal involvement are related to the substantia nigra involvement in ALS. Thus, nigrosome 1 could be a marker of a multisystem degeneration, which in turn associates to poor prognosis.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Gamb&#xed;n</LastName><ForeName>Mar&#xed;a Isabel</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Neurosonology Laboratory, Department of Neurology, Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tembl</LastName><ForeName>Jos&#xe9; I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Neurosonology Laboratory, Department of Neurology, Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maz&#xf3;n</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Radiology and Biomedical Imaging Research Group (GIBI230), Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;ada-Mart&#xed;nez</LastName><ForeName>Antonio Jos&#xe9;</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Instituto de Investigaci&#xf3;n Sanitaria la Fe (IIS La Fe), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;-Bonmat&#xed;</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Radiology and Biomedical Imaging Research Group (GIBI230), Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevilla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>ALS Unit, Department of Neurology, Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Research Unit, Instituto de Investigaci&#xf3;n Sanitaria La Fe (IIS La Fe), Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez-Costa</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3043-7938</Identifier><AffiliationInfo><Affiliation>ALS Unit, Department of Neurology, Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Spain. juan.vazquez@uv.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Research Unit, Instituto de Investigaci&#xf3;n Sanitaria La Fe (IIS La Fe), Valencia, Spain. juan.vazquez@uv.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain. juan.vazquez@uv.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Valencia, Valencia, Spain. juan.vazquez@uv.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JR19/00030 PI</GrantID><Agency>Instituto de Salud Carlos III (ES)</Agency><Country/></Grant><Grant><GrantID>19/01178 PI</GrantID><Agency>Instituto de Salud Carlos III (ES)</Agency><Country/></Grant><Grant><GrantID>2018/135</GrantID><Agency>Conselleria de Sanitat Universal i Salut P&#xfa;blica</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Hyperechogenicity of substantia nigra</Keyword><Keyword MajorTopicYN="N">Nigrosome 1</Keyword><Keyword MajorTopicYN="N">Primary lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Progressive muscular atrophy</Keyword><Keyword MajorTopicYN="N">Ultrasound</Keyword></KeywordList><CoiStatement>Dr. V&#xe1;zquez-Costa served on advisory boards for Biogen and Roche and received travel and speaker honoraria from Biogen and Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34379200</ArticleId><ArticleId IdType="pmc">PMC8857168</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10729-w</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10729-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Onodera O, et al. Sporadic amyotrophic lateral sclerosis: Two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008;116:169&#x2013;182. doi: 10.1007/s00401-008-0385-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0385-z</ArticleId><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65:636&#x2013;641. doi: 10.1001/archneur.65.5.636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.5.636</ArticleId><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Yilmaz R, Berg D. Developments in the role of transcranial sonography for the differential diagnosis of Parkinsonism. Curr Neurol Neurosci Rep. 2015 doi: 10.1007/s11910-015-0566-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-015-0566-9</ArticleId><ArticleId IdType="pubmed">26008814</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008;7:1044&#x2013;1055. doi: 10.1016/S1474-4422(08)70239-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70239-4</ArticleId><ArticleId IdType="pubmed">18940694</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson&#x2019;s disease and its relation to clinical findings. J Neurol. 2001;248:684&#x2013;689. doi: 10.1007/s004150170114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150170114</ArticleId><ArticleId IdType="pubmed">11569897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou HY, Sun Q, Tan YY, et al. Substantia nigra echogenicity correlated with clinical features of Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2016;24:28&#x2013;33. doi: 10.1016/j.parkreldis.2016.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2016.01.021</ArticleId><ArticleId IdType="pubmed">26842545</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between Parkinsonism and idiopathic Parkinson disease. Arch Neurol. 2007;64:1635&#x2013;1640. doi: 10.1001/archneur.64.11.1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.11.1635</ArticleId><ArticleId IdType="pubmed">17998447</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D. Substantia nigra hyperechogenicity is a risk marker of Parkinson&#x2019;s disease: yes. J Neural Transm. 2011;118:613&#x2013;619. doi: 10.1007/s00702-010-0565-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0565-6</ArticleId><ArticleId IdType="pubmed">21207077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann A, Reuner U, Schaefer J, et al. The diagnostic value of midbrain hyperechogenicity in ALS is limited for discriminating key ALS differential diagnoses. BMC Neurol. 2015;15:33. doi: 10.1186/s12883-015-0280-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-015-0280-x</ArticleId><ArticleId IdType="pmc">PMC4379542</ArticleId><ArticleId IdType="pubmed">25879789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathinia P, Hermann A, Reuner U, et al. Parkinson&#x2019;s disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis. J Neurol. 2013;260:454&#x2013;457. doi: 10.1007/s00415-012-6654-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6654-8</ArticleId><ArticleId IdType="pubmed">22923257</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Schenk A, Witte OW, et al. Transcranial brainstem sonography as a diagnostic tool for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15:244&#x2013;249. doi: 10.3109/21678421.2014.881499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.881499</ArticleId><ArticleId IdType="pubmed">24555439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlovic AM, Stevic Z, Pekmezovic T, et al. Increased frequency of pathologic findings on transcranial b-mode parenchymal sonography in patients with sporadic amyotrophic lateral sclerosis. Ultrasound Med Biol. 2015;41:982&#x2013;988. doi: 10.1016/j.ultrasmedbio.2014.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultrasmedbio.2014.12.005</ArticleId><ArticleId IdType="pubmed">25701529</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer KJ, Behnke S, Liepelt I, et al. Cross-sectional study discloses a positive family history for Parkinson&#x2019;s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm. 2007;114:1167&#x2013;1171. doi: 10.1007/s00702-007-0725-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-007-0725-5</ArticleId><ArticleId IdType="pubmed">17446999</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Costa JF, Tembl JI, Forn&#xe9;s-Ferrer V, et al. Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity. Sci Rep. 2017;7:7119. doi: 10.1038/s41598-017-07835-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07835-z</ArticleId><ArticleId IdType="pmc">PMC5541052</ArticleId><ArticleId IdType="pubmed">28769074</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey LA, Yousry TA. Anatomy of the substantia Nigra and Subthalamic nucleus on MR imaging. Neuroimaging Clin N Am. 2010;20:7&#x2013;27. doi: 10.1016/j.nic.2009.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nic.2009.10.001</ArticleId><ArticleId IdType="pubmed">19959016</ArticleId></ArticleIdList></Reference><Reference><Citation>Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999;122:1421&#x2013;1436. doi: 10.1093/brain/122.8.1421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.8.1421</ArticleId><ArticleId IdType="pubmed">10430829</ArticleId></ArticleIdList></Reference><Reference><Citation>Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson&#x2019;s disease. Brain. 1999;122:1437&#x2013;1448. doi: 10.1093/brain/122.8.1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.8.1437</ArticleId><ArticleId IdType="pubmed">10430830</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazejewska AI, Schwarz ST, Pitiot A, et al. Visualization of nigrosome 1 and its loss in PD. Neurology. 2013;81:534&#x2013;540. doi: 10.1212/WNL.0b013e31829e6fd2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31829e6fd2</ArticleId><ArticleId IdType="pmc">PMC3775686</ArticleId><ArticleId IdType="pubmed">23843466</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz ST, Afzal M, Morgan PS, et al. The &#x201c;swallow tail&#x201d; appearance of the healthy nigrosome&#x2014;a new accurate test of Parkinson&#x2019;s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS ONE. 2014 doi: 10.1371/journal.pone.0093814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093814</ArticleId><ArticleId IdType="pmc">PMC3977922</ArticleId><ArticleId IdType="pubmed">24710392</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau MT, Todd G, Wilcox R, et al. Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson&#x2019;s disease: a systematic review and meta-analysis. Park Relat Disord. 2020;78:12&#x2013;20. doi: 10.1016/j.parkreldis.2020.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2020.07.002</ArticleId><ArticleId IdType="pubmed">32668370</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh Y, Sung YH, Lee J, Kim EY. Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. Am J Neuroradiol. 2015;36:2010&#x2013;2016. doi: 10.3174/ajnr.A4412.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A4412</ArticleId><ArticleId IdType="pmc">PMC7964859</ArticleId><ArticleId IdType="pubmed">26294646</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J, de Jong JMBV, de Visser M. The history of progressive muscular atrophy: syndrome or disease? Neurology. 2008;70:723&#x2013;727. doi: 10.1212/01.wnl.0000302187.20239.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000302187.20239.93</ArticleId><ArticleId IdType="pubmed">18299524</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647&#x2013;653. doi: 10.1212/01.wnl.0000200962.94777.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000200962.94777.71</ArticleId><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis CM, Simmons A, Jones DK, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999;53:1051&#x2013;1058. doi: 10.1212/wnl.53.5.1051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.53.5.1051</ArticleId><ArticleId IdType="pubmed">10496265</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascenzo C, Cecchin D, Santelli L, et al. Parkinson-like features in ALS with predominant upper motor neuron involvement. Amyotroph Lateral Scler. 2012;13:137&#x2013;143. doi: 10.3109/17482968.2011.603732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.603732</ArticleId><ArticleId IdType="pubmed">21870999</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18:153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivo-Orti MN, Tembl JIJJI, Sastre-Bataller I, et al. Evaluation of the substantia nigra by means of transcranial ultrasound imaging: evaluaci&#xf3;n de la sustancia negra mediante ultrasonograf&#xed;a transcraneal. Rev Neurol. 2013;56:268&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">23440754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J, Shimizu H, Ohta K, et al. amyotrophic lateral sclerosis with pallidonigroluysian degeneration: a clinicopathological study. Ann Neurol. 2019 doi: 10.1002/ana.25652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25652</ArticleId><ArticleId IdType="pubmed">31773773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord. 2010;25:1868&#x2013;1875. doi: 10.1002/mds.23200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23200</ArticleId><ArticleId IdType="pubmed">20669307</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Chi&#xf2; A, Pagani M, et al. Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. J Neurol. 2019;266:1633&#x2013;1642. doi: 10.1007/s00415-019-09305-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09305-0</ArticleId><ArticleId IdType="pubmed">30949819</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, Linke R, Schwarz J, et al. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry. 1998;65:263&#x2013;265. doi: 10.1136/jnnp.65.2.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.65.2.263</ArticleId><ArticleId IdType="pmc">PMC2170216</ArticleId><ArticleId IdType="pubmed">9703186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bruneteau G, Munerati E, et al. Extrapyramidal stiffness in patients with amyotrophic lateral sclerosis. Mov Disord. 2009;24:2143&#x2013;2148. doi: 10.1002/mds.22762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22762</ArticleId><ArticleId IdType="pubmed">19735090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wais V, Rosenbohm A, Petri S, et al. The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurol Scand. 2016 doi: 10.1111/ane.12713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12713</ArticleId><ArticleId IdType="pubmed">27858953</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis&#x2014;a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9:708&#x2013;714. doi: 10.1038/nrneurol.2013.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciola A, Milardi D, Anastasi GP, et al. A direct cortico-nigral pathway as revealed by constrained spherical deconvolution tractography in humans. Front Hum Neurosci. 2016;10:374. doi: 10.3389/fnhum.2016.00374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnhum.2016.00374</ArticleId><ArticleId IdType="pmc">PMC4960230</ArticleId><ArticleId IdType="pubmed">27507940</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Costa JF, Arlandis S, Hervas D, et al. Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder. J Neurol Sci. 2017;378:130&#x2013;136. doi: 10.1016/j.jns.2017.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.04.053</ArticleId><ArticleId IdType="pubmed">28566149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>